COMMUNIQUÉS West-GlobeNewswire

Vystar Enters Final Testing of Breakthrough Dialysis Water Filtration Technology
29/01/2026
FEC Expands Reach Into New Vertical Markets Vystar plans to apply Fluid Energy Conversion (FEC) technology to increase pathogen killing efficiency, reduce size and cost of Vystar’s RxAir air purifiers. FEC technology [...]
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children
29/01/2026
Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Committee for Medicinal Products for Human Use (‘CHMP’) of the European Medicines Agency has adopted a positive opinion recommending the granting of [...]
Gameto Licenses Foundational Meiosis IP from Harvard to Advance Human Ovary-in-a-Dish Platform
29/01/2026
Newly licensed intellectual property enables genetic induction of early meiosis, further strengthening Gameto’s best-in-class platform for modeling human ovarian development and disease AUSTIN, Texas, Jan. 29, 2026 ( [...]
Father–Daughter Duo Brings Patented Recovery Sleeves to Target.com
29/01/2026
Tampa, FL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- While many Americans remain focused on their new year’s resolutions, there are also many living in pain, recovering from an injury or surgery and looking desperately for a [...]
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
29/01/2026
The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic [...]
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
29/01/2026
- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal [...]
Alira Health Opens the Registration for the Third Edition of the Global Payer Forum
29/01/2026
An Annual Global Event Examining the Key Trends Reshaping Access to Healthcare Innovation FRAMINGHAM, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alira Health today opens the registration for the third edition of its [...]
JenaValve Appoints John Molyneux to Vice President of Operations
29/01/2026
IRVINE, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the appointment of John Molyneux to Vice [...]
Elevar Therapeutics Names Dong-Gun Kim CEO as It Focuses on Post-NDA Commercialization Strategy
29/01/2026
Former CEO Dr. Bryan Kim will retain current role as CEO of Verismo Therapeutics FORT LEE, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Group and a fully [...]
Panakeia publishes landmark clinical validation showing AI can deliver rapid molecular profiling for colorectal cancer
29/01/2026
Panakeia publishes landmark clinical validation showing AI can deliver rapid molecular profiling for colorectal cancer Largest real-world, blinded, multi-site validation of AI molecular profiling from routine diagnostic [...]
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy
29/01/2026
TAIWAN, Jan. 29, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations [...]
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform
29/01/2026
RUTHERFORD, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel [...]
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
29/01/2026
Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patient The unconfirmed partial response (uPR) that was observed in the first scan has been achieved at [...]
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
29/01/2026
DOYLESTOWN, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific [...]
SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference
29/01/2026
DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call
29/01/2026
DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 [...]
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
29/01/2026
REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first [...]
Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension
29/01/2026
NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company” or “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare [...]
Fedora Pharmaceuticals Highlights Efficacy of Novel Antibiotic, FPI-2119, against Antimicrobial-resistant Gram-negative Bacteria at the 2026 IMARI Conference
29/01/2026
FPI-2119 offers potential solution to multi-drug-resistant Gram-negative infections EDMONTON, Alberta , Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat [...]

Pages